Chen Siqing, Qin Zhang, Zhou Sainan, Xu Yin, Zhu Ying
Department of Gastroenterology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
The Fourth Hospital of Changsha (Changsha Hospital Affiliated with Hunan Normal University), Changsha, Hunan, China.
Front Med (Lausanne). 2025 Mar 25;12:1569328. doi: 10.3389/fmed.2025.1569328. eCollection 2025.
Ulcerative colitis (UC) is a chronic idiopathic inflammatory disease affecting the colon and rectum. Characterized by recurrent attacks, UC is often resistant to traditional anti-inflammatory therapies, imposing significant physiological, psychological, and economic burdens on patients. In light of these challenges, innovative targeted therapies have become a new expectation for patients with UC. A crucial pathological feature of UC is the impairment of the intestinal mucosal barrier, which underlies aberrant immune responses and inflammation. Intestinal stem cells (ISCs), which differentiate into intestinal epithelial cells, play a central role in maintaining this barrier. Growing studies have proved that regulating the regeneration and differentiation of ISC is a promising approach to treating UC. Despite this progress, there is a dearth of comprehensive articles describing the role of ISCs in UC. This review focuses on the importance of ISCs in maintaining the intestinal mucosal barrier in UC and discusses the latest findings on ISC functions, markers, and their regulatory mechanisms. Key pathways involved in ISC regulation, including the Wnt, Notch, Hedgehog (HH), Hippo/Yap, and autophagy pathways, are explored in detail. Additionally, this review examines recent advances in ISC-targeted therapies for UC, such as natural or synthetic compounds, microbial preparations, traditional Chinese medicine (TCM) extracts and compounds, and transplantation therapy. This review aims to offer novel therapeutic insights and strategies for patients who have long struggled with UC.
溃疡性结肠炎(UC)是一种影响结肠和直肠的慢性特发性炎症性疾病。UC具有反复发作的特点,通常对传统抗炎疗法耐药,给患者带来了巨大的生理、心理和经济负担。鉴于这些挑战,创新的靶向治疗已成为UC患者的新期望。UC的一个关键病理特征是肠黏膜屏障受损,这是异常免疫反应和炎症的基础。分化为肠上皮细胞的肠干细胞(ISCs)在维持这一屏障中起核心作用。越来越多的研究证明,调节ISC的再生和分化是治疗UC的一种有前景的方法。尽管取得了这一进展,但缺乏全面描述ISC在UC中作用的文章。本综述重点关注ISC在维持UC肠黏膜屏障中的重要性,并讨论ISC功能、标志物及其调节机制的最新发现。详细探讨了参与ISC调节的关键途径,包括Wnt、Notch、Hedgehog(HH)、Hippo/Yap和自噬途径。此外,本综述还研究了针对UC的ISC靶向治疗的最新进展,如天然或合成化合物、微生物制剂、中药提取物和化合物以及移植治疗。本综述旨在为长期受UC困扰的患者提供新的治疗见解和策略。